GlassScriptPhysician profile
John F Mackenzie
NPI 1518078807
$6,955.09
in general payments reported to CMS, 2019-2025
38 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $197 · 2021: $859 · 2022: $1,896 · 2023: $1,616 · 2024: $468 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.33 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,609.82 | 2020-2025 | |
| Ucb, INC. | $621.03 | 2019-2023 | Briviact, Nayzilam |
| Acadia Pharmaceuticals INC | $414.15 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $396.76 | 2019-2025 | Ajovy, Austedo Xr |
| Allergan, INC. | $331.10 | 2019-2022 | |
| Medtronic, INC. | $316.15 | 2021-2025 | Sensight |
| Novartis Pharmaceuticals Corporation | $283.51 | 2019-2025 | |
| Biogen, INC. | $274.26 | 2019-2025 | Vumerity |
| Alexion Pharmaceuticals, INC. | $248.33 | 2021-2025 | Ultomiris |
| Genentech USA, INC. | $223.61 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Sunovion Pharmaceuticals INC. | $205.09 | 2021-2022 | |
| Celgene Corporation | $193.07 | 2021-2025 | Zeposia |
| Emd Serono, INC. | $169.74 | 2019-2023 | Mavenclad |
| Amgen INC. | $160.25 | 2019-2025 | Uplizna |
| Medtronic USA, INC. | $152.56 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $141.11 | 2022-2025 | Apokyn |
| Acorda Therapeutics, INC | $140.60 | 2019-2022 | |
| Genzyme Corporation | $122.28 | 2019-2023 | |
| Horizon Therapeutics Plc | $120.91 | 2021-2023 | Uplizna |
| Amneal Pharmaceuticals LLC | $93.47 | 2019-2025 | Crexont, Rytary |
| Biohaven Pharmaceutical Holding Company LTD. | $82.22 | 2022 | |
| Lilly USA, LLC | $81.62 | 2019-2023 | Emgality, Reyvow |
| Sk Life Science, INC. | $75.63 | 2022-2023 | |
| Pfizer INC. | $66.74 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $61.04 | 2021 | |
| Argenx US, INC. | $54.27 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Supernus Pharmaceuticals, INC. | $46.92 | 2019 | |
| Neurelis, INC. | $46.87 | 2022-2025 | Valtoco |
| Tanabe Pharma America, INC. | $44.84 | 2019-2024 | |
| Eisai INC. | $34.87 | 2022-2023 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Livanova USA, INC. | $19.56 | 2019 | |
| Grifols USA, LLC | $19.31 | 2023 | Gamunex-C |
| Corium, LLC | $18.13 | 2023 | Adlarity |
| Boston Scientific Corporation | $17.39 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.99 | 2019 | |
| Ge Healthcare | $15.81 | 2020 | |
| Lundbeck LLC | $15.08 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mackenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.